Relmada Therapeutics Inc (RLMD)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.17-2.34%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · RLMD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name operates in a high-miss-rate industry and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
RLMD — earnings miss
Dated 2026-05-12
Results of Operations and Financial Condition. On May 12, 2026, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the three months ended March 31, 2026. The Company also announced that it would conduct a conference call and audio webcast on Tuesday, May 12, 2026, at 4:30 PM EST / 1:30 PM PST, to discuss the update and results. The Company’s complete unaudited condensed consolidated financial statements and no…
Why it matters: FDA clearance would let Relmada begin its main late-stage test. The trial start would move NDV-01 into registrational testing.
Supportive ifAfter IND clearance, Relmada announces that the Phase 3 RESCUE trial has started and is enrolling patients.
Worry ifThe FDA places the IND on clinical hold, or Relmada reports that trial start is delayed after clearance.
Why it matters: Relmada says its cash can fund operations through 2029, including the NDV-01 Phase 3 program. Higher cash use could weaken that claim.
Worry ifQuarterly operating cash use stays near or below $9.6 million, the Q2 level. Management keeps its runway estimate through 2029.
Less concerning ifQuarterly operating cash use rises far above $9.6 million. Management now expects its cash to last until before 2029.
Why it matters: The filing is the next step toward the planned Phase 3 RESCUE trial. A delay would push back the program start.
Supportive ifRelmada files the NDV-01 IND with the FDA by December 31, 2026.
Worry ifRelmada reports that the IND filing missed the end of 2026. Or it says key manufacturing work is not done.
Why it matters: This would move Relmada's second lead program toward a human test in Prader-Willi Syndrome. The syringe system is the last stated step before filing.
Supportive ifRelmada files the sepranolone IND by December 31, 2026. It then reports a trial start after FDA clearance.
Worry ifThe IND filing misses the end of 2026. Or the company says the pre-filled syringe system is still not done.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$178 on $10,000 · ±1.8% | How much price usually moves either way. |
| Bad day | $733 loss on $10,000 · 7.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,056 loss on $10,000 · 60.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.